Methotrexate drug interaction study aims to boost safety
NCT ID NCT07196449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests how two drugs, rifampicin and cyclosporine, change the way methotrexate is processed in the body. Twelve healthy adult men will take methotrexate with either rifampicin or cyclosporine, and blood samples will measure drug levels. The goal is to identify potential interactions that could affect methotrexate's safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methotrexate, Rifampicin, Cyclosporine
- What this could lead to
- If successful, this could help doctors adjust methotrexate doses when given with other drugs, reducing side effects and improving safety.
- What could go wrong
- This is a small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world use, and no direct treatment benefit is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION (DDI) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13605, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new drug alter the fate of common medications?
- Tiny study checks if two drugs clash in the body
- New drug combo aims to shrink hard-to-treat tumors
- New drug safety check: how does JP-1366 mix with heart meds?
- New drug interaction study completed in 12 healthy volunteers
- New antibiotic combo tested in healthy volunteers – no cure yet